Ketamine in Borderline Personality Disorder
Mental Health & Behavioral Research
What is the purpose of this trial?
The purpose of this study is to test the potential of the rapid-acting anti-depressant ketamine to decrease suicidality in Borderline Personality Disorder (BPD).
The rate of completed suicide in BPD is similar to that of depression or schizophrenia. There is currently no specific medication treatment for BPD.
Ketamine is an FDA-approved anesthetic agent that has been shown to rapidly decrease suicidality and improve mood in people with Major Depressive Disorder (MDD). Though symptoms overlap, effective treatments for MDD and BPD differ. This clinical trial tests if ketamine also decreases suicidality and improves mood in BPD.
This trial will also measure several other outcomes after ketamine versus placebo in BPD: adverse events, BPD symptoms, pain, social cognition, and neuroplasticity.
- Ages21 - 45 years
- Trial withAmerican Foundation for Suicide Prevention
- Start Date01/14/2018
- End Date08/30/2022
- Last Updated08/15/2019
- Study HIC#2000021457